Rev Med Interne 2016 Oct 13
[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].
Related Questions
New answer by at Georgetown University Hospital (September 19, 2023)
I think of anifrolumab particularly for patients with cutaneous disease. The TULIP-2 trial showed promise for anifrolumab in these patients as a secondary endpoint. In patient...
Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...
New comment by at Uniformed Services University of the Health Sciences (USUHS) ( March 1, 2023)
I order mycophenolic levels to ensure of adherence in my MMF and Myfortic patients. We really do not know of therapeutic level goals in our lupus patients.